Onconova Therapeutics Files European Clinical Trial Applications for Global Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes

By: via Benzinga
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.